ZL-1102 is under clinical development by Zai Lab and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase II drugs for Plaque Psoriasis (Psoriasis Vulgaris) have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ZL-1102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ZL-1102 overview

ZL-1102 is under development for the treatment of mild to moderate psoriasis. It is applied topically. The drug candidate is a human antibody. It targets interleukin 17-A. The therapeutic candidate is developed based on VH technology that utilizes VH fragments to retain binding affinity and specificity.

Zai Lab overview

Zai Lab is a commercial-stage biopharmaceutical company. It discovers, develops and commercializes innovative products in the areas of oncology, autoimmune disorders, infectious disease and neuroscience. The company offers products such as niraparib, tumor-treating fields, efgartigimod, ripretinib and omadacycline. It’s pipeline products include tisotumab vedotin, adagrasib, repotrectinib, bemarituzumab, zipalertinib, ZL-1218, ZL-1310, sulbactam-durlobactam, KarXT, ZL-1102, ZL-8301, Efgartigimod PH20 SC, ZL-2308 (repotrectinib), ZL-1307 (REGN1979/odronextamab) and ZL-1218. Zai Lab commercializes its products under the brand names Optune, Qinlock, Zejula, NUZYRA and VYVGART. The company operates through its subsidiaries in Hong Kong, Taiwan, China, Australia and the US, among others. Zai Lab is headquartered in Shanghai, China.

For a complete picture of ZL-1102’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.